Ultragenyx Pharmaceutical Inc. (RARE)
RARE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1515673/000119312526057329/0001193125-26-057329-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | RARE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001515673 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $673.0M |
| Net income | -$575.0M |
| Operating income | -$535.0M |
| Net margin | -85.4% |
| Operating margin | -79.5% |
| Revenue growth | +20.2% |
| Cash | $421.0M |
| Total assets | $1.5B |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 2.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-04 |
| Cash and burn | $150.0M cash; operating cash flow -$109.3M a quarter. | Report 2026-09-30 |
| Shares outstanding | 101,924,068 (2026-10-29); 96,477,569 a year earlier; 82,114,350 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, San Mateo, California, United States | PCAOB Form AP 2026-03-09 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $4.0M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $173.0M | -$118.0M | -$43.0M | $150.0M | No debt tags | $730.0M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $214.0M | -$92.0M | -$97.0M | $125.0M | No debt tags | $717.0M | 10-Q 2026-08-05 |
| Q1 2026 2026-03-31 | $136.0M | -$185.0M | -$197.0M | $175.0M | No debt tags | $670.0M | 10-Q 2026-05-06 |
| Q4 2025 2025-12-31 | $207.0M | -$129.0M | -$100.0M | $421.0M | No debt tags | $673.0M | 10-K 2026-02-18 |
| Q3 2025 2025-09-30 | $160.0M | -$180.0M | -$91.0M | $203.0M | No debt tags | $630.6M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $167.0M | -$115.0M | -$109.0M | $176.0M | No debt tags | $610.1M | 10-Q 2026-08-05 |
| Q1 2025 2025-03-31 | $139.0M | -$151.0M | -$166.0M | $127.0M | No debt tags | $590.2M | 10-Q 2026-05-06 |
| Q4 2024 2024-12-31 | $164.6M | -$133.2M | -$79.3M | $174.0M | No debt tags | $560.0M | 10-K 2026-02-18 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-06-14 |
| Latest annual report | 10-K | 2026-02-18 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report | 8-K | 2026-11-03 |
| Latest proxy | DEFA14A | 2026-04-30 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.2% |
| 1 month | +7.8% |
| 3 months | -39.0% |
| Year to date | -30.1% |
| 1 year | -51.1% |
| From 52-week high | -56.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SRPT | Sarepta Therapeutics Inc. Common Stock (DE) | $15.13 | -5.85% | $1.6B |
| ANIP | ANI Pharmaceuticals Inc. | $70.89 | -0.77% | $1.6B |
| NRIX | Nurix Therapeutics Inc. | $14.73 | -4.84% | $1.6B |
| KLRA | Kailera Therapeutics Inc. | $12.57 | -5.28% | $1.6B |
| ADRX | ADARx Pharmaceuticals Inc. | $14.00 | -1.41% | $1.6B |
| PGEN | Precigen Inc. | $4.30 | -5.29% | $1.5B |
| QURE | uniQure N.V. | $21.88 | -8.11% | $1.5B |
| SLS | SELLAS Life Sciences Group Inc. | $7.47 | -4.96% | $1.5B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier